Spruce Biosciences, Inc. (SPRB)
After hours:
| Previous close | 1.4300 |
| Open | 1.4300 |
| Bid | 1.3500 x 800 |
| Ask | 1.5400 x 1000 |
| Day's range | 1.3600 - 1.4400 |
| 52-week range | 1.2500 - 6.4800 |
| Volume | |
| Avg. volume | 30,149 |
| Market cap | 32.277M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.8860 |
| Earnings date | 14 Nov 2022 - 18 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 9.17 |
- Business Wire
Spruce Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
SAN FRANCISCO, August 30, 2022--Spruce Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
- Business Wire
Spruce Biosciences Reports Second Quarter 2022 Financial Results and Provides Corporate Update
SAN FRANCISCO, August 10, 2022--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2022 and provided corporate updates.
- Business Wire
Spruce Biosciences to Participate in June Investor Conferences
SAN FRANCISCO, June 01, 2022--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in two upcoming investor conferences taking place in June.
